AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01504412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
Study NCT01504412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin capsules
Description: Pregabalin oral capsules 150 mg administered twice a day
Study NCT03045718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horticultural Therapy
Description: The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
Study NCT03045718 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Horticultural Therapy
Description: The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
Study NCT00511134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
Study NCT00850954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information on secondhand smoke and supporting smoker in quitting
Study NCT00850954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive smoking cessation materials based on TTM
Study NCT00511134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
Study NCT00511134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
Study NCT00767806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 60 mg orally once daily for 12 weeks
Study NCT00767806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily orally for 12 weeks
Study NCT03226834 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MUSIC CARE
Description: Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles
Study NCT03226834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PERSONAL PLAY-LIST
Description: Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
Study NCT01983085 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NOx dressing
Description: The NOx dressing should be changed at least every 2 days.
Study NCT01983085 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care
Description: Dressing changed as per normal clinical practice
Study NCT00742183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex
Description: Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
Study NCT00742183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silvadene
Description: Silvadene - dressing changes every day, more frequently if needed
Study NCT01590407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-002200
Description: ALS-002200
Study NCT01590407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00207142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + 2 NRTIs
Description: Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
Study NCT00207142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + Ritonavir + 2 NRTIs
Description: Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
Study NCT00207142 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir + Ritonavir + 2 NRTIs
Description: Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
Study NCT03742141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative Video Laryngoscopy
Description: The IOVL is a disposable, otherwise standard fiberoptic laryngoscope that is inserted alongside the endotracheal tube following intubation for surgical procedures.
Study NCT03742141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: 0.004mg/kg as per routine prior to intubation
Study NCT00375843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
Study NCT00375843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
Study NCT02961699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpose ® RT System
Description: adipose-derived stem cell therapy
Study NCT02961699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: debridement/dressing of wound
Description: standard of care debridement and wound dressing
Study NCT01192152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: Tablets, Oral, 5 mg, once daily, Single dose
Study NCT01192152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage XR
Description: Tablets, Oral, 500 mg, once daily, Single dose
Study NCT01192152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin + metformin XR (FDC tablet)
Description: Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
Study NCT00850954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT00649337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography
Description: AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.~The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed.
Study NCT01680315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low calorie yogurt
Description: all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
Study NCT01680315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high calorie yogurt
Description: all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
Study NCT02161588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
Study NCT02161588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily oral administration as tablets.
Study NCT02632630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acids w/Electrolytes in Dextrose
Description: Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
Study NCT02632630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure product
Description: Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
Study NCT02632630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid solutions
Description: Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
Study NCT02632630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral nutritional supplementation
Description: Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
Study NCT01072058 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TNF blockers (infliximab, adalimumab, etanercept)
Description: Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
Study NCT01816165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
Study NCT01816165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
Study NCT04595825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - intravenous infusion
Study NCT03801070 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopic drainage of walled off pancreatic necrosis
Description: transmural drainage and mechanical debridement of solid debris (necrosectomy)
Study NCT01757795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8203
Description: SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
Study NCT01757795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be intravenously administered
Study NCT01484691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
Study NCT01418365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole + MMX Mesalazine/mesalamine placebo
Description: Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
Study NCT01418365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole + MMX Mesalazine/mesalamine
Description: Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
Study NCT00830726 — intervention group
Intervention type: DRUG
Intervention: Pharmacologic and mechanical heart failure treatment
Description: Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
Study NCT03675061 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Current care
Description: Tocolysis and a complete corticosteroid treatment.
Study NCT03675061 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PartoSure Test negative
Description: Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
Study NCT03675061 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PartoSure Test positive
Description: Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
Study NCT02463370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: suprazygomatic maxillary area infiltration
Description: Local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas.
Study NCT02375672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
Study NCT02375672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion
Study NCT04578847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Initial dose - 400 mg daily. If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
Study NCT04944589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROOT CANAL TREATMENT
Description: Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.
Study NCT02463370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-suprazygomatic maxillary area placebo
Description: The remaining injections at supratrochlear area, medial to the medial canthus, nasal still and anterior septum are placebo (saline)
Study NCT02463370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-suprazygomatic maxillary area infiltration
Description: Local anesthetic infiltration in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum.
Study NCT02463370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: suprazygomatic maxillary area placebo
Description: The remaining maxillary injection is placebo.
Study NCT04716647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ayurveda
Description: Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.
Study NCT04578847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Initial dose - 300 or 400 mg twice daily. If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.
Study NCT04578847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Initial dose 100 or 140 mg daily. If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.
Study NCT04578847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Initial dose 500 mg daily. If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.
Study NCT04594850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram-ED
Description: Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.
Study NCT00058825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Study NCT01849965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSC127
Description: DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
Study NCT00830726 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
Study NCT00830726 — intervention group
Intervention type: PROCEDURE
Intervention: Revascularisation in Acute Coronary Syndrome
Description: Standard percutaneous or surgical revascularisation in ACS.
Study NCT00830726 — intervention group
Intervention type: PROCEDURE
Intervention: Revascularisation in chronic stable angina pectoris
Description: Standard percutaneous or surgical revascularisation
Study NCT02549391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: Oral administration
Study NCT02549391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRN1493
Description: Oral administration
Study NCT01849965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vehicle gel
Study NCT01849965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care gel, Aquasite
Study NCT01593397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and Fentanyl administration
Description: Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
Study NCT04523207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
Study NCT00058825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -5 to Day -2: Fludarabine 30 mg/m2.
Study NCT00058825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Day 0: Donor stem cells infused.
Study NCT00058825 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
Study NCT00058825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506 (Tacrolimus) or Cyclosporine
Description: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
Study NCT01531699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT005 Ophthalmic Prep Solution
Description: single application for up to 6 hours
Study NCT01531699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline control
Description: single application for up to 6 hours
Study NCT01531699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine ophthalmic prep solution
Description: single application for up to 6 hours
Study NCT03337204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted self-monitoring
Description: Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
Study NCT03337204 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology-assisted self-monitoring
Description: Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
Study NCT04552366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV
Description: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Study NCT03337204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop and Peer Mentoring
Description: Participants receive a 3-hour Engaged4Life Workshop (psychoeducation + goal setting) and one-on-one peer mentoring via phone 2X/week for 3 weeks.